Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
October 18 2021 - 8:00AM
Business Wire
Fireside Chat with B. Riley Research
Scheduled for 12:30pm Eastern
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, today announced that Lineage
will be featured in the B. Riley Securities Fall 2021 “Growth
Biotech Best Idea” Virtual Series, in a fireside chat hosted by
Mayank Mamtani, Managing Director, Senior Biotech Research Analyst
and Group Head of Healthcare Research at B. Riley Securities. The
fireside chat will feature Lineage management, including, Brian M.
Culley, Chief Executive Officer, Kevin Cook, Chief Financial
Officer, and Gary Hogge, Senior Vice President of Clinical and
Medical Affairs. The Lineage team will be joined by Jordi Monés,
M.D., Ph.D., Director, Institut de la Màcula, Director and
Principal Investigator, Barcelona Macula Foundation: Research for
Vision. Interested investors can register to join the live event
today at 9:30am Pacific / 12:30pm Eastern here.
Therapeutic Area Expert
Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula,
Director and Principal Investigator, Barcelona Macula Foundation:
Research for Vision.
Dr. Monés is an ophthalmologist, macula and vitreoretinal
specialist, and macular and retinal degeneration researcher. Dr.
Monés earned his medical degree at the University of Barcelona and
subsequently specialized in ophthalmology at Barraquer
Ophthalmology Centre. He completed his retinal specialist training
at the Massachusetts Eye and Ear Infirmary at Harvard University,
and at Hospital San José, Monterrey Institute of Technology and
Higher Education. He earned his PhD degree in Medicine and Surgery
at the University of Barcelona. Dr Monés is dedicated to fighting
blindness by supporting and conducting research in retinal disease.
For the last 15 years he has been one of the foremost researchers
involved in clinical trials for the treatment of age-related
macular degeneration. He is currently conducting Phase I, II and
III clinical trials. His work has been widely published in
scientific journals and he has given more than 200 presentations at
international congresses. He is a member of 12 scientific
societies.
Interested parties can register to view both the live event and
replay on the Events and Presentations section of Lineage’s
website. Additional videos are available on the Media page of the
Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC2, an allogeneic dendritic cell therapy produced from
Lineage’s VAC technology platform for immuno-oncology and
infectious disease, currently in Phase 1 clinical development for
the treatment of non-small cell lung cancer. For more information,
please visit www.lineagecell.com or follow the Company on Twitter
@LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211018005115/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Mike Biega (Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2023 to Apr 2024